Financial insights of VCYT

MyFinsight

For the quarter ending 2025-09-30, VCYT made $131,872,000 in revenue. $19,137,000 in net income. Net profit margin of 14.51%.

Unit: Dollar

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total revenue	131,872,000	130,164,000	114,473,000	101,161,500
Cost of revenue-Testing	33,777,000	32,407,000	-	-
Cost of revenue-Product	3,015,000	1,749,000	-	-
Cost of revenue	-	-	32,380,000	34,264,000
Cost of revenue-Biopharmaceutical And Other	1,091,000	3,572,000	-	-
Intangible asset amortization - cost of revenue	2,707,000	2,667,000	2,585,000	9,439,500
Total cost of revenue	40,590,000	40,395,000	34,965,000	43,703,500
Gross profit	91,282,000	89,769,000	79,508,000	70,611,000
Research and development	15,981,000	16,264,000	17,720,000	17,627,500
Selling and marketing	24,455,000	25,316,000	24,454,000	24,303,000
General and administrative	27,278,000	32,331,000	33,808,000	26,561,500
Impairment of assets	0	20,505,000	-	842,000
Intangible asset amortization - operating expenses	-	-	622,000	768,000
Intangible asset amortization - operating expenses-Intangible Asset Amortization	622,000	621,000	-	-
Total operating expenses	68,336,000	95,037,000	76,604,000	70,851,500
Income from operations	22,946,000	-5,268,000	2,904,000	-240,500
Other income (loss), net	-4,057,000	6,518,000	4,524,000	1,008,000
Income before income taxes	18,889,000	1,250,000	7,428,000	767,500
Income tax (benefit) provision	-248,000	2,230,000	381,000	-857,000
Net income	19,137,000	-980,000	7,047,000	1,624,500

Basic (in shares)	78,725,139	78,392,000	78,028,254	-38,533,698.5
Basic (in usd per share)	0.24	-0.01	0.09	0.025
Diluted (in shares)	79,691,703	78,392,000	80,056,024	-38,732,293
Diluted (in usd per share)	0.24	-0.01	0.09	0.025